Valuation: Vivoryon Therapeutics N.V.

Market Cap 18.66M 20.48M 17.19M 15.64M 29.34M 1.9B 30.83M 209M 83.16M 1.04B 76.86M 75.24M 3.25B P/E 2026 *
-1.66x
P/E 2027 * -1.7x
Enterprise Value 22.98M 25.23M 21.17M 19.26M 36.13M 2.34B 37.97M 258M 102M 1.28B 94.65M 92.66M 4B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.15%
Yield 2026 *
-
Yield 2027 * -
1 day-1.56%
1 week-17.97%
Current month-21.45%
1 month-31.07%
3 months-44.00%
6 months-49.40%
Current year-55.63%
1 week 0.6
Extreme 0.604
0.77
1 month 0.52
Extreme 0.522
0.91
Current year 0.52
Extreme 0.522
1.65
1 year 0.52
Extreme 0.522
1.65
3 years 0.41
Extreme 0.41
9.93
5 years 0.41
Extreme 0.41
20.64
10 years 0.41
Extreme 0.41
23.25
Manager TitleAgeSince
Chief Executive Officer 66 2023-08-13
Director of Finance/CFO - 2025-11-30
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 56 2006-12-31
Director/Board Member 66 2023-09-14
Director/Board Member 58 -
Date Insider Type Main position Quantity % Market Cap. Importance
10/23/25 Free

Chief Operating Officer

20,000 0.0767%
10/23/25 Buy

Chief Executive Officer

135,000 0.5179%
10/23/25 Free 20,000 0.0767%
Change 5-day change 1-year change 3-year change Capi.($)
-1.56%-17.97%-60.62%-92.33% 20.48M
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.39%-2.89%+24.24%+148.50% 40B
Weighted average by Cap. -1.48%-1.85%+32.15%+150.89%

Financials

2026 *2027 *
Net sales - -
Net income -10.4M -11.42M -9.58M -8.72M -16.35M -1.06B -17.19M -117M -46.36M -578M -42.84M -41.94M -1.81B -10.4M -11.42M -9.58M -8.72M -16.35M -1.06B -17.19M -117M -46.36M -578M -42.84M -41.94M -1.81B
Net Debt 4.32M 4.74M 3.98M 3.62M 6.79M 439M 7.14M 48.45M 19.26M 240M 17.8M 17.42M 753M 13.03M 14.31M 12.01M 10.92M 20.49M 1.32B 21.53M 146M 58.08M 724M 53.68M 52.54M 2.27B
Projected Income Statement - Annual - Vivoryon Therapeutics N.V.
Logo Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Vivoryon Therapeutics N.V. has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer.
Employees
13
Date Price Change Volume
26-11-20 €0.6300 -1.56% 11,856
26-11-19 €0.6400 -3.32% 12,354
26-11-18 €0.6620 -6.76% 93,521
26-11-17 €0.7100 -2.74% 14,501
26-11-16 €0.7300 -4.95% 32,985
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6300EUR
Average target price
6.850EUR
Spread / Average Target
+987.30%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Vivoryon Therapeutics N.V.